|
|
Home > Healthcare > Medical > Diagnostics
Disruption or Advantage? Update on Companion Diagnostics
|
| Published Date:
September 2009
Published By:
Decision Resources
Page Count:
25
Order Code:
R55-675
|
|
|
|
Introduction
Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders.
Companion diagnostics combines drug and diagnostic test development. The potential for effi cient drug development
is huge because companion diagnostics can be used to predict drug response and treatment effi cacy—
therefore, companion diagnostics are also the perfect means to fulfi llment of the promise of personalized
medicine. But the advantages of companion diagnostics are only one side of the equation: they are also seen as
disruptors of the pharmaceutical market that could restrict the size of treatable populations. Bringing the differing
viewpoints together to form a unifi ed idea of what companion diagnostics really mean to the industry is a
challenge, but one that companies must heed because companion diagnostics are making their mark—like it or
not.
Questions Answered in This Report
- Regulatory and payer decisions on certain types of testing are increasingly infl uencing physician, patient, and
industry perspectives. For instance, how has the FDA’s recent decision to alter the Vectibix and Erbitux
labels affected industry dynamics?
- Companies that have developed companion diagnostics are viewed as valuable acquisition targets. Which
companies are attracting potential buyers? What is the perceived impact of these acquisitions on the
overall strategies of pharmaceutical companies?
- The availability of companion diagnostics in oncology is greater than in other therapy areas. Why is oncology
such an attractive area for growth in personalized medicine? In what other areas is development of
personalized medicine growing?
Scope
- Stakeholder analysis: Pharmaceutical companies, diagnostics companies, payers, regulatory agencies,
physicians, and patients.
- Recent trends and decisions: Regulating KRAS mutation tests, identifi cation of genetic markers of
response to Vanda’s Fanapt (iloperidone), reimbursement for warfarin testing, partnering and dealmaking
in companion diagnostics.
- Indications: Non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer, heart
failure, arthritis, depression, chronic myelogenous leukemia (CML).
- Company profi les: Pharmaceutical companies—Wyeth, Vanda Pharmaceuticals, Roche, Pfi zer,
Novartis, Johnson & Johnson, Eli Lilly, ARCA BioPharma, Amgen, and Abbott. Diagnostics companies—
LabCorp, DxS, Dako, and Clinical Data.
- Outlook: Spectrum Expert Commentary on future growth, therapeutic area emphasis, the promise of personalized medicine
|
Similar Products
• Testing Laboratories
Published Nov 2009 by First Research, Inc.
• Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
Published Nov 2009 by Kalorama Information
• Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies
Published Nov 2009 by Venture Planning Group
• The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Published Oct 2009 by Kalorama Information
• Three Alternative Scenarios Of The Future In Vitro Diagnostics Market 2009-2018
Published Oct 2009 by Venture Planning Group
• Preventive Healthcare Technologies, Products and Markets
Published Oct 2009 by BCC Research
• 2009 Worldwide Diagnostics Market Research Bundle
Published Oct 2009 by Kalorama Information
• Veterinary Diagnostics Markets
Published Oct 2009 by Kalorama Information
• Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook
Published Oct 2009 by Business Insights
|
|
|
|
0 items
